Insilico Medicine Launches PandaClaw AI Agent and Expands Partnership with ASKA to Transform Women’s Health Drug Discovery

Sharing a familiar ‘Claw’ in its name, PandaClaw joins the AI spotlight as Insilico Medicine today revealed its next-generation agent designed to accelerate drug discovery and advance treatments in women’s health. Building on the company’s PandaOmics platform, PandaClaw enables biologists to perform complex multi-omics analyses using simple natural language commands, bridging the gap between computational biology and laboratory expertise.

AI Meets Biology, Streamlining Target Discovery

Drug discovery has long required dual expertise in biomedicine and artificial intelligence, a combination that can take years to cultivate. PandaClaw simplifies this process. The platform features three key components:

Agent Core – guides research workflows, following the logic of experienced biologists.

Proprietary Data Warehouses – curated datasets for reliable, actionable insights.

Skills Library – more than 140 scientific skills and 1,000+ bioinformatics tools, designed by veteran experts.

Researchers can now input their objectives in plain language. PandaClaw automatically generates multi-step plans, pulling data from PandaOmics, external databases, and proprietary datasets. The platform ensures secure sandboxing, real-time error correction, and rich reporting while maintaining full data provenance and scientific transparency.

“PandaClaw is not just a search engine. It’s an autonomous AI agent that mirrors the decision-making of expert biologists and bioinformaticians,” said Dr. Frank Pun, Head of Insilico Medicine Hong Kong. “It delivers real-time multi-omics analyses with deep biological annotation and statistical validation, enabling faster, more actionable insights.”

Expanding Women’s Health Innovation with ASKA Pharmaceutical

In a strengthened collaboration with ASKA Pharmaceutical, Insilico is applying PandaClaw to tackle gynecological conditions such as endometriosis, uterine fibroids, and adenomyosis—conditions affecting hundreds of millions of women globally. PandaOmics identifies promising therapeutic targets, which ASKA validates in preclinical studies.

“Preclinical validation of AI-nominated targets for endometriosis shows that AI can generate actionable insights in complex women’s health biology,” said Dr. Pun.

Dr. Shuzo Watanabe, Director of ASKA’s Innovative Drug Discovery Research Division, added: “By leveraging AI across all stages of research, we can accelerate the identification of high-quality targets and bring innovative therapies to patients faster.”

The partnership utilizes TargetPro models, which integrate multi-modal biological data to predict clinical success, outperforming traditional target identification methods and nominating candidates ready for immediate validation.

PandaClaw Setting New Benchmarks in Preclinical Development

Insilico has demonstrated remarkable efficiency in early-stage drug discovery. Whereas traditional programs take an average of 4.5 years, Insilico completes projects in 12–18 months, testing only 60–200 molecules per program. Between 2021 and 2024, the company successfully nominated 20 preclinical candidates, establishing new industry benchmarks for AI-driven drug discovery.

PandaClaw reflects Insilico’s vision of pharmaceutical superintelligence, transforming raw computational data into actionable mechanistic insights. Researchers achieve expert-level results without compromising scientific rigor, accelerating the translation of discoveries into clinical applications.

PandaClaw Driving Impact Across AI Drug Discovery and Women’s Health

PandaClaw makes sophisticated AI analyses accessible to researchers worldwide, supporting real-time target prioritization, mechanistic interpretation, and multi-omics studies. By applying AI to the most pressing challenges in women’s health, Insilico aims to shorten the timeline from discovery to therapy, potentially bringing novel treatments to patients sooner. 

“PandaClaw represents the next step in AI-enabled drug discovery, turning complex datasets into meaningful biological insights that can drive real-world impact,” Dr. Pun concluded.

Author

Steven Chung

紅杏枝頭春意鬧固然是眾人所追求的風景，但我願意說，青蘿拂行衣更能湧生感嘆。 願在海量晦澀的生醫資訊中，為您點亮一座心燈塔。鐘煌翔